NCT00461786View on ClinicalTrials.gov

A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

October 31, 2007

Study Completion Date

May 31, 2008

Conditions
Ovarian CancerPeritoneal Cancer
Interventions
DRUG

pemetrexed

900 mg/m2, intravenous (IV), every 21 days, until disease progression

Trial Locations (1)

Unknown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Philadelphia

All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

Eli Lilly and Company

INDUSTRY

NCT00461786 - A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter